Elsayed Abo-Salem, MD
Interventional Cardiology · Saint Louis, MONPI 1629207477
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Livanova USA, Inc. at 43.5% of the total. Reporting peaked in 2022 at $8,177 and has fallen 70.4% since, to $2,417 in 2025.
Across 331 payments — averaging $84.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$12K
- Abbott$4K
- Abiomed$3K
- Edwards Lifesciences$3K
- Cardiovascular Systems Inc.$1K
- Shockwave Medical, Inc$728
- plus $4K from 25 others
Across 7 payments — averaging $31,071 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$162K
- Cardiovascular Systems Inc.$56K
What the payments were for
- Speaking & faculty fees$11,00439%
- Travel & lodging$4,71417%
- Food & beverage$12,22944%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 16 | $12,164 |
| Abbott | 55 | $3,921 |
| Abiomed | 30 | $3,365 |
| Edwards Lifesciences | 24 | $2,547 |
| Cardiovascular Systems Inc. | 8 | $1,276 |
| Shockwave Medical, Inc | 46 | $728 |
| Medtronic(2 entities) | 5 | $601 |
| Amgen | 24 | $444 |
| Boston Scientific | 7 | $373 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $344 |
| Novartis | 20 | $333 |
| Merck | 15 | $284 |
| Pfizer | 12 | $236 |
| Penumbra, Inc. | 2 | $195 |
| Boehringer Ingelheim | 8 | $174 |
| Chiesi USA, Inc. | 8 | $147 |
| Cvrx, Inc. | 1 | $136 |
| E.r. Squibb & Sons, L.L.C. | 5 | $117 |
| Sanofi-aventis U.S. LLC | 5 | $112 |
| Novo Nordisk | 4 | $69 |
| AstraZeneca | 4 | $68 |
| Johnson & Johnson | 3 | $64 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $52 |
| Bayer | 3 | $46 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Biosense Webster, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $21 |
| Teleflex LLC | 1 | $20 |
| Impulse Dynamics (USA) Inc. | 1 | $16 |
| Heartflow, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeSPARC$6,250
- TandemLife$5,388
- Impella$2,174
- AMPLATZER AMULET$2,034
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,240
- Peripheral Orbital Atherectomy System$1,100
- MitraClip$344
- COREVALVE EVOLUT R$314
- TandemHeart$284
- SAPIEN 3 Ultra RESILIA$239
- MitraClip System$227
- Indigo$150
- CoreValve Evolut$145
- AVVIGO Guidance System$141
- Barostim Neo System$136
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$133
- CentriMag$128
- Resolute$125
How this compares
$27,947 in reported general payments places this provider in the 75th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 276 | $240,741 |
| XareltoRivaroxaban | 117 | $105,858 |
| CamzyosMavacamten | 11 | $93,063 |
| EntrestoSacubitril/Valsartan | 49 | $51,899 |
| JardianceEmpagliflozin | 62 | $41,001 |
| BrilintaTicagrelor | 21 | $18,479 |
| Ranolazine ErRanolazine | 25 | $3,960 |
| Metoprolol Succinate | 168 | $1,850 |
| Atorvastatin Calcium | 203 | $1,819 |
| Furosemide | 295 | $1,554 |
| ClopidogrelClopidogrel Bisulfate | 169 | $1,412 |
| Losartan Potassium | 117 | $1,307 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 132 | $1,053 |
| Ezetimibe | 56 | $1,044 |
| Amiodarone Hcl | 42 | $833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $236 | $240,741276 claims |
| Johnson & JohnsonXarelto | $64 | $105,858117 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $117 | $93,06311 claims |
| NovartisEntresto | $333 | $51,89949 claims |
| Boehringer IngelheimJardiance | $174 | $41,00162 claims |
| AstraZenecaBrilinta | $68 | $18,47921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Saint Louis
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
- Gus TheodosSaint Louis$165K
- Prashanth ThakkerSaint Louis$129K
- Marc SintekSaint Louis$119K
- George KichuraSaint Louis$118K
- Gil VardiSaint Louis$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.